Anti hypertensive Activities of Standardised *Moringa oleifera* Lam. (Merunggai) Exports in Spontaneously Hypertensive Rats  

(Aktiviti Antihipertensi Menggunakan Ekstrak *Moringa oleifera* Lam. (Merunggai) Piawai pada Tikus Hipertensi Secara Spontan) 

ENDANG KUMOLOSASI, CHENG CHEN WEI, ANIS ZAFIQA ABDULLAH, NUR SYAIHRAH ABD MANAP, WOON LEE LEE, MOHD HANIF YUSUF, LO SHIN YING, FHATAHEYA BUANG, MAZLINA MOHD SAID, HAZNI FALINA MOHAMAD & MALINA JASAMAI* 

**ABSTRACT** 

In recent years, *Moringa oleifera* has received commercial interest for its blood pressure (BP)-lowering effect. The objectives of this study were to investigate the hypotensive, diuretic, and angiotensin converting enzyme (ACE)-inhibitory activities of *M. oleifera* ethanolic and aqueous extracts. Spontaneously hypertensive (SH) and normotensive (NT) rats were fed the ethanolic and aqueous extracts at a dose of 1000 mg/kg each for 14 days. The rats were allocated to 12 groups of five rats each. Systolic and diastolic BP were measured, and urine was collected. All extracts, except the aqueous stem extract, significantly reduced systolic and diastolic BP in SH rats, but none of the extracts showed significant hypotensive effects on NT rats. The ethanolic leaf extract (ELE) caused significant diuresis. Moreover, most of the extracts inhibited ACE activity significantly at 40 and 80 µg/mL. ELE, aqueous leaf extract (ALE), and ethanolic pod extract (EPE) showed the highest levels of inhibition (>50%), and their IC₅₀ values; ELE (58.65±1.55), ALE (71.35±1.00) and EPE (54.04±1.00) were determined. The hypotensive effect observed was achieved either by diuretic or ACE-inhibitory activity. The active extracts are worthy of further investigation, as they have the potential to be developed as dietary supplements for pre-hypertensive individuals. 

**Keywords:** ACE inhibition; diastolic blood pressure; diuretic; *Moringa oleifera*; systolic blood pressure 

**INTRODUCTION** 

Obesity, dyslipidaemia, and hypertension have been reported as the most prevalent risk factors associated with cardiovascular diseases in Malaysia (Amiri et al. 2014). Alarmingly, despite awareness and improvements in the health care system, the prevalence of hypertension in Malaysian adults aged over 30 years has been a rising trend from 2006 to 2015 (Ab Majid et al. 2018). Hypertensive patients, defined as those with persistent elevation of systolic blood pressure (BP) of 140 mmHg or greater and/or diastolic BP of 90 mmHg or greater (MOH 2013), are managed with pharmacological treatments. In contrast, pre-hypertensive individuals, defined as those with systolic BP of 120 to 139 mmHg or diastolic BP of
80 to 89 mmHg, are managed with non-pharmacological treatments, including dietary supplements (MOH 2013). Herbal supplements such as ginseng, garlic, ginger, gingko biloba, echinacea, and Hawthorn have gained popularity for preventing cardiovascular diseases. Locally, merunggai (Malay) or Moringa oleifera Lam. (syn. M. peregrisperma Gaertn.), which belongs to the Moringaceae family, has been reported to exert negative inotropic effect (Dangi et al. 2002) and diuretic activity (Cáceres et al. 1992).

The history of M. oleifera dates back to 150 BC, when ancient kings and queens used its leaves and fruits in their diet for extra energy and to relieve stress and pain (Mahmood et al. 2010). Most of the plant parts have been used traditionally in Southeast Asia for various ailments, including as a cardiac circulatory tonic and diuretic (Khare 2007; Nadkarni 2009). M. oleifera has high nutritional value: the leaves are rich in vitamins A and C (Lim 2007), and the seeds contain high amounts of magnesium and calcium (Amaglo et al. 2010). The leaves and young pods are usually used in cooking. M. oleifera is also rich in simple sugars (glucosinolates and isothiocyanates) (Fahey et al. 2001), alkaloids (moringin and moringinine) (Nellis 1997), flavonoids (kaempferol, rhammetin, isouqueritrin, and kaempferitrin) (Siddhuraju & Becker 2003), amino acids (methionine, cystine, tryptophan, and lysine) (Lim 2012), and fatty acids (oleic oils and tocopherols) (Rossell & Pritchard 1991). The diverse bioactive compounds present in this highly valued plant might contribute to the various pharmacological activities observed. Moreover, M. oleifera, which has shown good safety profiles, is abundant in Malaysia (Asare et al. 2012).

The hypotensive effect of M. oleifera has been reported in previous studies (Faizi et al. 1998, 1994), and may be attributed to the presence of glycosides (thiocarbamate, isothiocyanate, and mustard oil) (Faizi et al. 1995), methyl p-hydroxybenzoate, β-sitosterol (Faizi et al. 1998), niazin A, niazin B, niazimicin, and both niazimin A and B (Faizi et al. 1994) in the pods, seeds, roots, and leaves. Different parts of M. oleifera have also been shown to exhibit diuretic activity (Cáceres et al. 1992). However, information on the hypotensive effect of the stems and twigs is still lacking. Moreover, the action mechanism of the blood pressure-lowering effect has not been fully explored, and little is known on the effect of these plant parts on non-hypertensive individuals.

Ethanolic and aqueous extracts of the stems and twigs of M. oleifera might show a similar hypotensive effect as that reported for other plant parts (Faizi et al. 1998, 1995, 1994). This effect might be due to diuresis or disruption in the renin-angiotensin pathway, as these are among the common action mechanisms of antihypertensive agents. The hypotensive effect might not be observed in non-hypertensive individuals, as in the case of garlic supplements (Wang et al. 2015). In this study, the hypotensive effects of different M. oleifera ethanolic and aqueous extracts were evaluated in spontaneously hypertensive (SH) and normotensive (NT) rats. The diuretic and angiotensin converting enzyme (ACE)-inhibitory activities of these extracts were also investigated.

MATERIALS AND METHODS

RATS AND CHEMICALS

SH rats were purchased from the Animal Unit of University Malaya, and Sprague-Dawley rats were purchased from the Animal Unit of Universiti Kebangsaan Malaysia (UKM). The reference standards used in this study were purchased from Wuhan ChemFaces Biochemical Co., Ltd. (Wuhan, China) [β-sitosterol, 98% purity by high-performance liquid chromatography (HPLC); campesteryl, 98% purity by HPLC], Extrasynthese (Lyon, France) (kaempferol-3-O-rutinoside, 98% purity by HPLC; stigmasterol, 90% purity by HPLC; chlorogenic acid, 99% purity by HPLC), and Sigma Aldrich Malaysia (octacosanoic acid, 98% purity by HPLC; lisinopril, 98% purity by HPLC; tragacanth). The positive controls for the in vivo study were clinically used drugs: perindopril 5 mg (Coversyl®; Servier), ibesarian 150 mg (Aprovel®; Sanofi Aventis), and hydrochlorothiazide 12.5 mg (Hydrochlorothiazide®; Royce Pharma).

PREPARATION OF PLANT PARTS

M. oleifera plant parts (the leaves, twigs, stems, roots, pods, and seeds) were obtained from a farm in Kuala Terengganu, Terengganu in October 2015. The plant was identified and authenticated by Professor Emeritus Dato’ Dr. Abdul Latiff Mohamad of the Faculty of Science, University Malaya, and a voucher specimen (HF-133) was deposited in the UKM Herbarium. The plant parts were cut into small pieces, dried, ground, and stored at room temperature (29 °C) until use.

The ground M. oleifera plant parts were extracted with water and ethanol. Water extraction was performed by boiling plant materials (100 g) in distilled water (0.15 L) for 6 h. The extracts were filtered and stored at -80 °C for 3 days prior to being freeze-dried (Rathi et al. 2006), and the powdered extracts obtained were stored at -20 °C until use. Ethanol extraction was performed by maceration. Plant parts (500 g) were soaked in 95% ethanol (at a ratio of one plant part to six parts of ethanol) for 3 days at room temperature (29 °C). The extracts were filtered, and the filtrate was concentrated under vacuum to obtain a dark green gummy extract. The residues were macerated twice. The extracts were stored at 4°C until use.

Tragacanth suspension was prepared by dissolving 3 g of tragacanth powder in 300 mL distilled water prior
to preparation of test samples and controls. Tragacanth suspension was used as a negative control (NC). Next, plant part extracts (4.9 g), perindopril [positive control 1 (PC1)] (9.8 mg), irbesartan [positive control 2 (PC2)] (98 mg), and hydrochlorothiazide (positive control [PC], 29.4 mg) were dissolved in 35 mL of 1% tragacanth before being fed to rats. Drug doses were calculated based on dose conversion from humans to animals (Laurence & Bacharach 1964), and the dose used for the extracts was determined in a preliminary study conducted prior to the actual study.

**STANDARDISATION OF M. oleifera EXTRACTS**

Chemical markers were dissolved in HPLC-grade methanol to produce standard solutions of 1.0 mg/mL for ß-Sitosterol, kaempferol-3-O-rutinoside, and stigmasterol as well as 0.5 mg/mL for chlorogenic acid and campesterol. Octacosanolic acid was prepared as a 0.5 mg/mL solution in methanol and chloroform (7:3). M. oleifera ethanolic and aqueous extracts were accurately weighed (1.0 g), dissolved in 10 mL distilled water, mixed thoroughly by vortexing, sonicated for 15 min, and centrifuged for 5 min at 4000 rpm. The supernatant was collected and filtered with a 0.45-µm membrane filter prior to injection into the HPLC column. A HPLC system (Waters 1515 Isocratic HPLC pump) with a dual wavelength absorbance detector (Waters 2487) was utilised to analyse the general profiles of phytochemical compounds in the plant extracts and to quantify the compound content. The HPLC column (5 µm C18 column, XBridge Reversed-Phase) was set at room temperature (29 °C) at a flow rate of 1.0 mL/min. HPLC-grade methanol and water were mixed at a ratio of 70:30 (v/v) and used as mobile phase. The mobile phase was filtered and degassed for 15 min before use. Samples (20 µL) were injected with a running time of 10 min, and peaks were detected at 205 nm. The accuracy, precision, and specificity of the method were determined for method validation.

**DETERMINATION OF SYSTOLIC AND DIASTOLIC BP**

The research was conducted in accordance with the internationally accepted principles for laboratory procedures and care of animals as described in the European Community guidelines (EEC Directive of 1986; 86/609/EEC). The experimental procedure was approved by the UKM Animal Ethics Committee (FF/2016/ MALINA/18-MAY/754-MAY-2016-JAN.-2018) on 18th May 2016. Rats were maintained in the Faculty Animal House, caged in a group of three, and provided pelleted feed and water ad libitum. A 12-h dark and light cycle was maintained. Systolic and diastolic BP were measured using a CODA high-throughput tail-cuff system (CODA-HT2) (Daugherty et al. 2009). Briefly, the infra-red warming platform was preheated at 32-35 °C, and a rat was allowed to enter freely into a plastic restraint of appropriate size on the platform. The nose cone on the restraint was adjusted, and the rat was left in the restraint without human handling for 10-15 min. An occlusion cuff was placed at the base of the tail, followed by a volume pressure recording cuff. The temperature of the tail was maintained at 32-35 °C throughout the experiment using a warming cover.

In a preliminary study to determine an effective dose, SH rats were allocated into four treatment groups of three rats each. Each group was treated with PC1, NC, low-dose (500 mg/kg) M. oleifera ethanolic leaf extract (ELE), or high-dose (1000 mg/kg) ELE. Feeding of rats with doses higher than 1000 mg/kg was difficult owing to the viscosity of the extract. Rats were fed orally once daily for 7 consecutive days, and BP was measured on days 1 and 7 of the study.

In a preliminary study to determine the BP-lowering effects of M. oleifera extracts on NT rats, 18 Sprague-Dawley rats weighing 200-300 g were randomly divided into six groups of three rats each. NC, ELE, aqueous leaf extract (ALE), ethanolic twig extract (ETE), ethanolic seed extract (ESE), and ethanolic root extract (ERE) were administered to each group. Extracts and controls were administered to the rats by oral gavage once daily for 14 days. The administered volume of extract suspensions was adjusted daily according to the weight of rats (1 mL/100 g).

The BP-lowering effects of M. oleifera plant part extracts were investigated in 60 male adult SH rats weighing 200-300 g. They were randomly divided into 12 groups of five rats each. Each group of rats was fed NC, PC1, PC2, ELE, ALE, ETE, ethanolic pod extract (EPE), aqueous pod extract (APE), ESE, ethanolic stem extract (EEE), aqueous stem extract (AEE), or ERE. Five NT rats were used as controls in this study. Systolic and diastolic BP were measured prior to the administration of extracts and controls on day 1 and day 15 post-treatment. Reductions in systolic and diastolic BP were the differences between the values obtained on day 0 and those obtained on day 15.

**EVALUATION OF DIURETIC ACTIVITY**

Diuretic activity was determined on day 14 of the study. Rats were deprived of food but not water for 18 h prior to urine collection. The groups receiving extracts and NC were fed as usual, and a group receiving positive control was fed hydrochlorothiazide. After the administration of extracts and controls, rats were placed individually in metabolic cages, and cumulative urine output was determined at hourly intervals for 5 h.
ACE INHIBITION ASSAY

The ACE-inhibitory activity of the extracts was determined using a method described by Agboola et al. (2010) with some modifications. Lisinopril (positive control), ELE, ALE, ETE, EPE, APE, ESE, EEE, and ERE were used in this study. Briefly, 80 µL of the positive control and extracts (4, 8, 10, 20, 40, 60, and 80 µg/mL) were dissolved in 0.1 M borate buffer containing 0.3 M NaCl (pH 8.3) and mixed with 20 µL ACE solution (0.1 U/mL). The mixture was incubated at 37 °C for 10 min. Next, 200 µL of 5.0 mM hippuryl-histidyl-leucine substrate was added, and the enzyme-substrate mixture was further incubated for 30 min at 37 °C. Enzymatic reaction was quenched by adding 0.05 M HCl (250 µL) to the reaction mixture. The produced hippuric acid was extracted by adding 1.7 mL ethyl acetate to the mixture, which was then shaken vigorously for 1 min and centrifuged for 5 min at 5000 rpm. The upper layer was placed in a vial and heated in a water bath to evaporate the ethyl acetate. The residue was dissolved in 1 mL distilled water, and absorbance was determined using a UV-visible spectrophotometer (Shimadzu UV Spectrophotometer UV1800) at 228 nm. A blank sample containing 0.05 M HCl (50 µL) was prepared and used to calculate the percentage inhibition (Agboola et al. 2010).

\[
\text{%ACE inhibition} = \left( \frac{\text{blank absorbance} - \text{sample absorbance}}{\text{blank absorbance}} \right) \times 100
\]

STATISTICAL ANALYSIS

Values obtained were analysed using PRISM software (5.0). Data are presented as mean±standard error of the mean (SEM) and statistical comparisons were conducted using the paired-sample t-test, one-way ANOVA, and Bonferroni post-hoc test. Significance was set at \( p \leq 0.05 \).

RESULTS

STANDARDISATION OF M. oleifera EXTRACTS

HPLC chromatograms of M. oleifera plant extracts (Table 1) showed the presence of different phytochemical compounds, which correspond to the respective standards used (chlorogenic acid, β-sitosterol, stigmasterol, campesterol, and kaempferol-3-O-rutinoside). The presence of the respective chemical markers was confirmed by spiking the extracts with the markers. Only extracts containing the phytochemical compounds mentioned were used in this study, namely ELE, ALE, ETE, EPE, APE, ESE, EEE, and AEE.

<table>
<thead>
<tr>
<th>Phytochemical compounds/ plant extracts</th>
<th>Retention time (min)</th>
<th>RSD (%)</th>
<th>Area (mAU)</th>
<th>Concentration (mg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlorogenic acid</td>
<td>5.226±0.145</td>
<td>0.014</td>
<td>40916458</td>
<td>1.00</td>
</tr>
<tr>
<td>ELE</td>
<td>6.515±0.040</td>
<td>0.000</td>
<td>36608919</td>
<td>0.895</td>
</tr>
<tr>
<td>ALE</td>
<td>5.33±0.120</td>
<td>0.013</td>
<td>83956154</td>
<td>1.026</td>
</tr>
<tr>
<td>β-Sitosterol</td>
<td>2.824±0.010</td>
<td>0.025</td>
<td>2270104</td>
<td>1.00</td>
</tr>
<tr>
<td>ETE</td>
<td>2.817±0.003</td>
<td>0.041</td>
<td>6437894</td>
<td>7.274</td>
</tr>
<tr>
<td>EPE</td>
<td>2.828±0.020</td>
<td>0.008</td>
<td>30891887</td>
<td>12.807</td>
</tr>
<tr>
<td>APE</td>
<td>2.79±0.048</td>
<td>0.025</td>
<td>25387830</td>
<td>11.095</td>
</tr>
<tr>
<td>Stigmasterol</td>
<td>4.278±0.003</td>
<td>0.017</td>
<td>1899873</td>
<td>1.00</td>
</tr>
<tr>
<td>ESE</td>
<td>4.425±0.020</td>
<td>0.016</td>
<td>7495848</td>
<td>3.952</td>
</tr>
<tr>
<td>Campesterol</td>
<td>4.276±0.003</td>
<td>0.017</td>
<td>1955984</td>
<td>0.500</td>
</tr>
<tr>
<td>ESE</td>
<td>4.425±0.020</td>
<td>0.016</td>
<td>6322866</td>
<td>1.918</td>
</tr>
<tr>
<td>Kaempferol-3-O-rutinoside</td>
<td>3.150±0.007</td>
<td>0.022</td>
<td>2230220</td>
<td>1.00</td>
</tr>
<tr>
<td>EEE</td>
<td>3.110±0.030</td>
<td>0.023</td>
<td>240386</td>
<td>0.056</td>
</tr>
<tr>
<td>AEE</td>
<td>3.20±0.087</td>
<td>0.022</td>
<td>527880</td>
<td>0.977</td>
</tr>
</tbody>
</table>

ELE, ethanolic leaf extract; ALE, aqueous leaf extract; ETE, ethanolic twig extract; EPE, ethanolic pod extract; APE, aqueous pod extract; ESE, ethanolic seed extract; EEE, ethanolic stem extract; AEE, aqueous stem extract
BP-LOWERING EFFECTS OF THE EXTRACTS

The parameters measured using the non-invasive tail-cuff method included systolic and diastolic BP. A preliminary study was conducted to determine the effective dose of the extract, and the results are presented in Figure 1. High-dose (1000 mg/kg) ELE significantly lowered the systolic (133.3±4.53 mm Hg) (p ≤ 0.001) and diastolic (83.07±12.20 mm Hg) (p ≤ 0.01) BP of SH rats compared with that of the NC rats. The effect of high-dose ELE was comparable with that of the positive control, as no significant differences were observed. No significant reduction in systolic and diastolic BP was observed with low-dose ELE (500 mg/kg). Thus, 1000 mg/kg was selected as the effective dose and used in the actual study. In the preliminary study of M. oleifera extracts on NT rats, ELE, ALE, ERE, ETE, and ESE did not show significant reduction in systolic and diastolic BP on day 15 compared with that of the NC (Figure 2).

**FIGURE 1.** Systolic (a) and diastolic (b) BP of SH rats after 7 days of treatment with M. oleifera ethanolic leaf extracts (preliminary study). NC: negative control (spontaneously hypertensive (SH) rats without treatment), PC1: positive control (SH rats administered perindopril), LD: SH rats administered low-dose extract (500 mg/kg), MD: SH rats administered medium-dose extract (1000 mg/kg), HD: SH rats administered high-dose extract (2000 mg/kg). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared with NC; #p ≤ 0.05, ##p ≤ 0.01, ###p ≤ 0.001 compared with PC1; n = 3

**FIGURE 2.** Systolic BP (a), systolic BP reduction (b), diastolic BP (c), and diastolic BP reduction (d) in NT rats after 14 days of treatment with Moringa oleifera plant part extracts (preliminary study). NT: normotensive rats (negative control), ELE: NT rats administered ethanolic leaf extract, ALE: NT rats administered aqueous leaf extract, ERE: NT rats administered ethanolic root extract, ETE: NT rats administered ethanolic twig extract, ESE: NT rats administered ethanolic seed extract; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 compared with NT; n=3
In the actual study, compared with the NC rats, the systolic and diastolic BP (Figure 3) of SH rats treated with ELE (121.40±5.11 mm Hg; 76.84±5.76 mm Hg), ALE (133.40±9.08 mm Hg; 98.05±7.33 mm Hg), ERE (128.90±1.68 mm Hg; 87.56±2.81 mm Hg), ETE (123.30±3.31 mm Hg; 81.56±8.55 mm Hg), and EPE (139.30±8.56 mm Hg; 99.36±6.88 mm Hg), and EEE (128.80±5.06 mm Hg; 95.87±3.50 mm Hg) significantly decreased after 14 days of treatment (p ≤ 0.05, p ≤ 0.001). However, ESE (134.90±13.41 mm Hg) and APE (126.70±19.68 mm Hg) only reduced systolic BP (p ≤ 0.01–p ≤ 0.001) and not diastolic BP. Moreover, significant reductions in systolic and diastolic BP were observed with ELE (81.88±7.22 mm Hg; 88.83±15.95 mm Hg), ALE (77.59±17.43 mm Hg; 67.93±21.14 mm Hg), ERE (53.90±1.22 mm Hg; 52.41±0.37 mm Hg), ETE (71.87±6.33 mm Hg; 58.90±10.11 mm Hg), and EEE (53.68±0.77 mm Hg; 48.63±0.52 mm Hg) (p ≤ 0.01–p ≤ 0.001). In contrast, EPE (47.08±8.63 mm Hg) reduced only systolic BP significantly (p < 0.001) and not diastolic BP.

**DIURETIC ACTIVITY OF THE EXTRACTS**

Figure 4 shows a significant increase in the urine output of SH rats treated with hydrochlorothiazide (6.36±1.14 mL) (p ≤ 0.001) and ELE (5.14±0.49 mL) (p ≤ 0.01) compared with that of the NC.
ACE-INHIBITORY ACTIVITY OF THE EXTRACTS

A preliminary study was conducted to determine the optimum concentration of extracts to be used in the study, and the results are shown in Figure 5. The lowest effective concentration of lisinopril (positive control) (36.50±1.30%) in inhibiting ACE activity was 1 µg/mL, and the highest concentration was 40 µg/mL (88.60±2.90%), showing significant differences (p<0.001) compared with the NC. For ELE, the lowest effective concentration was 40 µg/mL (46±3.97%) (p<0.05 compared with the NC) and the highest concentration was 80 µg/mL (57±9.75%) (p<0.01 compared with the NC). Thus, concentrations of 40 and 80 µg/mL were used in this study. The inhibitory effect of the extracts on ACE activity was shown to be dose-dependent.

FIGURE 5. Mean percentage of angiotensin converting enzyme (ACE) inhibition after treatment with various concentrations of lisinopril (a) and ELE (b), as well as after treatment with 40 µg/mL (c) and 80 µg/mL (d) extract. NC: negative control (borate buffer), ELE: spontaneously hypertensive (SH) rats administered ethanolic leaf extract, ALE: SH rats administered aqueous leaf extract, ERE: SH rats administered ethanolic root extract, ETE: SH rats administered ethanolic twig extract, ESE: SH rats administered ethanolic seed extract, EPE: SH rats administered ethanolic pod extract, AEE: SH rats administered aqueous pod extract, EEE: SH rats administered ethanolic stem extract. *p < 0.05, **p < 0.01, ***p < 0.001 compared with NC; n = 3
Compared with the NC, at 40 µg/mL, ELE (32.24±0.34%), ALE (34.56±0.25%), ETE (14.27±0.94%), EPE (12.72±0.94%), EEE (38.68±0.82%), and AEE (21.46±0.86%) significantly inhibited ACE activity. Furthermore, compared with that in the NC, ACE activity was significantly inhibited (p ≤ 0.01, p ≤ 0.001) by ELE (58.41±0.79%), ALE (51.05±1.10%), ETE (14.31±1.05), EEE (13.59±0.57), AEE (62.84±0.86%), EPE (14.38±0.94), EEE (40.31±1.32), and AEE (31.61±0.81%) at 80 µg/mL (Figure 5).

DISCUSSION

*M. oleifera* is rich in various phytochemical compounds. In this study, the presence of these chemical markers was confirmed by the following standards: chlorogenic acid, β-sitosterol, stigmasterol, campesterol, and kaempferol-3-O-rutinoside. Similar compounds have also been previously reported in various *M. oleifera* plant parts (Anwar et al. 2007; Leone et al. 2016; Ragasa et al. 2016; Sharma & Paliwal 2013; Vongsak et al. 2014).

A preliminary study showed that *M. oleifera* extracts did not lower systolic and diastolic BP in NT rats. This indicates that this plant may not cause hypotension in healthy individuals. A similar effect was observed with garlic, which lowers BP in hypertensive patients, but not in healthy individuals (Wang et al. 2015). Nevertheless, further studies are required to extrapolate the results obtained in this study to humans.

The effective dose (1000 mg/kg) used in this study was obtained from a preliminary study conducted prior to the actual study. Among the tested extracts, compared with the NC, only AEE did not exert BP-lowering activity. Nevertheless, none of these extracts showed significant BP-lowering effects compared with the positive controls (perindopril and irbesartan); therefore, it was concluded that the BP-lowering effects of these extracts are comparable to those of the positive controls.

The hypotensive activity of *M. oleifera* leaf, seed, and root extracts in SH rat models has been reported (Gilani et al. 1994; Kajihara et al. 2008). However, to the best of our knowledge, extracts of the other parts of *M. oleifera* have not been investigated in SH rats. The observed hypotensive activity of ELE, ALE, ERE, ETE, EPE, and EEE might be owing to the presence of bioactive compounds, such as niazinin A, niazinin B, niaziminic, niazicimic A, and B (Kajihara et al. 2008), nitrile, mustard oil glycosides, thiocarbamate glycosides (Anwar et al. 2007), 1,3-dibenzyyl urea, aurantiamide (Sashidhara et al. 2009), and methyl p-hydroxybenzoate (Faizi et al. 1998). These bioactive compounds were isolated from the leaves, twigs, and pods of *M. oleifera*. Similar activity was also observed in the aqueous leaf extract of *Moringa* (Mengistu et al. 2012).

On day 14, the urine output of SH rats treated with ELE was comparable to that of those administered hydrochlorothiazide, with no significant difference. A similar pattern of diuresis was reported in *M. oleifera* root, leaf, and flower aqueous extracts (Cáceres et al. 1992). However, in the present study, the diuretic activity of aqueous root extract was not significant compared with that of the NC. The observed diuretic activity of ELE might be owing to the presence of polar compounds, such as flavonoids, saponins, and organic acids (Maghrani et al. 2005). These polar compounds might inhibit tubular reabsorption of water and ions into the renal tubules, thus causing diuresis (Patel et al. 2009). Taken together, diuretic activity might contribute to the hypotensive effect observed with ELE.

In the ACE-inhibitory assay, ELE, ALE, and EPE showed significant inhibitory effects, with the latter having the highest level of inhibition (> 50%) at 80 µg/mL. The half-inhibitory concentrations (IC50) of these active extracts are presented in Table 2. The IC50 values of the three active extracts were significantly higher than that of lisinopril. This indicates that these extracts were effective in inhibiting ACE activity, but not as effective as lisinopril. The observed inhibitory effect might be owing to the presence of bioactive compounds, such as flavonoids (Ojeda et al. 2010), flavanols (Ottaviani et al. 2006), flavonols (Kwon et al. 2010), anthocyanins, isoflavones, flavones (Loizzo et al. 2007), and proteins (Garza et al. 2017). Similar ACE-inhibitory activities were observed in the seed (Garza et al. 2017) and leaf (Abdulazeexz et al. 2017) extracts of *M. oleifera*. These extracts are worthy of further development, as harvesting of the leaves and pods for medicinal uses will not be destructive to the plant.

<table>
<thead>
<tr>
<th>Substance</th>
<th>IC50 (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lisinopril</td>
<td>10.93±1.00</td>
</tr>
<tr>
<td>ELE</td>
<td>58.65±1.55***</td>
</tr>
<tr>
<td>ALE</td>
<td>71.35±1.00***</td>
</tr>
<tr>
<td>EPE</td>
<td>54.04±1.00***</td>
</tr>
</tbody>
</table>

ELE: spontaneously hypertensive (SH) rats administered ethanolic leaf extract, ALE: SH rats administered aqueous leaf extract, EPE: SH rats administered ethanolic pod extract. ***p < 0.001 compared with lisinopril
Most of the studied plant extracts reduced systolic and diastolic BP in SH rats, but had no significant effect in NT rats. This is an interesting finding, as *M. oleifera* might not cause hypotension if consumed by individuals with normal BP. Moreover, diuresis was observed in SH rats treated with ELE, which indicates that diuresis might be a mechanism underlying the hypotensive effect of this plant extract. Some plant parts (ELE, ALE, and EPE) also showed good (> 50%) inhibitory effect on ACE activity, which might contribute to the observed hypotensive effect. The observed hypotensive effects might also be owing to the presence of bioactive compounds that act on BP and ACE activity. The other plant parts that did not show good diuretic and ACE-inhibitory activities but significantly reduced systolic and diastolic BP in SH rats may have different action mechanisms. Future research on active extracts of *M. oleifera* should focus on other action mechanisms associated with hypotension; examples include the calcium channel, angiotensin, and β receptor-blocking activities. Active plant parts with known hypotensive effects can be potentially developed as dietary supplements for pre-hypertensive individuals.

ACKNOWLEDGEMENTS

The authors would like to thank Dr. Azmath Jaleel for his help in editing the manuscript and preparing the graphical abstract. This study was financially supported by the Ministry of Agriculture (MOA) of Malaysia (grant number: NH1015D073).

REFERENCES


